Heterozygous familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by an elevated low-density lipoprotein cholesterol (LDL-C) (\> 95th percentile for age and sex), clinical manifestations (tendinous xanthomas, xanthelasmas, and arcus cornealis), a family history of elevated LDL-C in a first-degree relative, or a personal or family history of premature (\< 55 years for men and 65 years for women) atherosclerotic cardiovascular disease (ASCVD).[@bib1] The diagnosis is confirmed in the presence of a causal mutation in the low-density lipoprotein receptor, apolipoprotein B, or proprotein convertase subtilisin/kexin type 9 (*PCSK9*) genes.[@bib2] As much as 20% of patients with FH do not have a single mutation in these causal genes, but an accumulation of single nucleotide polymorphisms in genes that are associated with an increase in LDL-C: a "polygenic LDL score."[@bib3] Prolonged exposure to high levels of LDL in patients with FH leads to the development of premature atherosclerosis. Compared with the general population, untreated patients with FH present with clinical ASCVD in the third decade for men and 10 years later in women. The prevalence of heterozygous FH is estimated at 1 of 250 in the general population and approximately 1 of 125 in patients with ASCVD.[@bib4], [@bib5], [@bib6]

Despite FH being the most common monogenic disorder encountered in clinical practice, it is often not recognized clinically. The reasons for this are complex and may relate to the difficulty for clinicians in applying the current definitions. The accepted definitions for FH include the Dutch Lipid Clinic Network and Simon Broome Register criteria, as well as a new Canadian definition.[@bib1], [@bib7] A diagnosis of FH relies on a baseline (ie, untreated) LDL-C level above 5 mmol/L in adults and clinical features with a point-based system that is often difficult to use in the clinical setting. Often, the baseline LDL-C is not available, because many patients are taking lipid-lowering drugs and the lack of electronic medical records makes it difficult to retrieve untreated LDL-C levels.

Therefore, a validated imputation was used to determine baseline LDL-C levels,[@bib8] and we examined the prevalence of FH in the **R**elating **E**vidence to **A**chieve **C**holesterol **T**argets (REACT) registry, based on accepted international criteria and a new Canadian definition for FH.[@bib7] We used a computer algorithm, integrated into a practical clinical application, to determine the diagnosis of FH based on the criteria mentioned earlier (<http://www.circl.ubc.ca/english/web_fh.html>).[@bib9]

Methods {#sec1}
=======

The REACT registry was established to examine the need for further intensification of lipid-lowering therapies in patients with FH or ASCVD who did not reach the recommended LDL-C targets, despite maximally tolerated statins ± ezetimibe. The subjects gave written informed consent for the study after receiving a detailed explanation of the purposes, potential benefits, and risks associated with participation. The protocol was approved by the Ethics Review Board, University of Western Ontario. All data were de-identified, and the investigators were blinded to the patient's physician or clinic of origin.

Inclusion criteria were as follows: (1) men and women aged \> 18 years; (2) the presence of ASCVD defined as a documented acute coronary syndrome or myocardial infarction according to international criteria, prior arterial revascularization, or angiographically documented coronary artery disease (\>50% cross-sectional stenosis of an epicardial coronary artery), the presence of documented cerebrovascular disease or peripheral arterial disease; or (3) the presence of FH defined by the treating physician according to accepted criteria (ie, documented physical signs of FH and presence of a first-degree relative with hypercholesterolemia or premature ASCVD as included in the Simon Broome Register[@bib10] or Dutch Lipid Clinic Network[@bib11] criteria); and (4) an LDL-C \> 3.0 mmol/L when untreated (mostly due to perceived statin intolerance) or despite maximally tolerated lipid-lowering treatment.

A validated imputation for baseline LDL-C levels based on average response to statin and ezetimibe was used to determine baseline or untreated LDL-C levels according to lipid-lowering therapy when the baseline LDL-C was not available.[@bib8] Then, a clinical application was used to determine the presence of FH according to internationally accepted criteria (Simon Broome Register, Dutch Lipid Clinic Network) and the new simplified Canadian definition of FH (<http://www.circl.ubc.ca/english/web_fh.html>).[@bib9] Confirmation of FH with a molecular diagnosis was not available in this cohort.

On the basis of the described criteria, patients were classified as "definite FH," "probable FH," and hypercholesterolemia. The algorithm used to diagnose FH according to the new simplified Canadian FH criteria is shown in [Figure 1](#fig1){ref-type="fig"}. For the comparison of the Canadian definition with the 2 mostly used clinical definitions of FH, the proportion of probable/definite FH in subgroups of patients referred to as "probable FH" and "definite FH" as defined by the Dutch Lipid Clinic Network criteria and the "possible" and "definite FH" as defined by the Simon Broome Register criteria were used.Figure 1Algorithm used to diagnose FH according to the simplified Canadian definition for the diagnosis of FH. \*Secondary causes of high LDL-C should be ruled out (severe or untreated hypothyroidism, nephrotic syndrome, hepatic disease or biliary cirrhosis, and medication, especially antiretroviral agents). \*\*Causal DNA mutation refers to the presence of a known FH-causing variant in the low-density lipoprotein receptor, apolipoprotein B*,* or *PCSK9* gene based on presence of the variant in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>), HGMD (<http://www.hgmd.cf.ac.uk/ac/index.php>), or WDLV (<https://www.ncbi.nlm.nih.gov/pubmed/23623477>) databases in the proband or a first-degree relative. ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol. Reproduced from Ruel et al.[@bib7] with permission from Elsevier.

The REACT cohort was then separated into 2 subgroups: patients who were included on the basis of a clinical diagnosis of FH made by their treating physician and those enrolled because of the presence of ASCVD. The actual prevalence of FH was then determined in both groups. This allowed for validation of the clinician's original diagnosis of FH, and for identification of "missed FH" patients in the ASCVD group. The study flow diagram is shown in [Figure 2](#fig2){ref-type="fig"}.Figure 2Flow diagram of the REACT registry. There were 195 subjects with ASCVD or a diagnosis of FH; 4 patients had both diagnoses and were included in the FH group (n = 109), and 86 patients were included in the ASCVD group. ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; low-density lipoprotein cholesterol; REACT, **R**elating **E**vidence to **A**chieve **C**holesterol **T**argets.

Statistical analyses {#sec1.1}
--------------------

Statistical analyses were performed using IBM SPSS Statistics (version 24.0, IBM Corp., Armonk, NY). Descriptive variables were calculated for the entire cohort and then according to the inclusion criterion subgroups (ASCVD or FH). Continuous variables with a normal distribution were presented as mean ± standard deviation. Student *t* tests were used to determine if variables differed significantly between the ASCVD and FH subjects. Differences in categorical variables were expressed as numbers and percentages, and a statistical difference between groups was examined by Pearson's chi-square test. *P* ≤ 0.05 was statistically significant.

Results {#sec2}
=======

As part of the REACT registry project, 195 patients with established ASCVD or FH (diagnosed based on traditional criteria) with an LDL-C level \> 3.0 mmol/L despite maximally tolerated statin therapy ± ezetimibe were prospectively enrolled. A validated imputation was used to determine baseline (untreated) LDL-C levels, along with other clinical criteria to determine prevalence of FH, using accepted international criteria and the new Canadian definition for FH.[@bib7] The enrolling physicians identified ASCVD in 90 patients and FH in 109 patients, with 4 patients having both. For the present analysis, we assigned the 4 patients with FH and ASCVD to the FH group. [Table 1](#tbl1){ref-type="table"} shows the demographic and clinical data of the REACT cohort and the FH and ASCVD subgroups.Table 1Baseline demographics of patientsCharacteristicREACT cohortFH inclusionASCVD inclusion*P* value FH vs ASCVDN19510986Men/women109/8661/4848/380.98Age, y (mean ± SD) \[range\]63 ± 12 \[28-89\]60 ± 12 \[28-87\]66 ± 10 \[40-89\]**\< 0.001**BMI, kg/m^2^ (mean ± SD)28.9 ± 5.129.0 ± 5.228.7 ± 4.850.64Cardiovascular disease reported for inclusion (%)46.2%3.7%100%**\< 0.001**Family history of ASCVD (%)59.5%74.3%40.7%**\< 0.001**Systemic hypertension (%)62.1%51.4%75.6%**\< 0.001**Type 2 diabetes (%)26.2%21.1%32.6%0.07Smoking (past and current) (%)37.9%34.9%41.9%0.32Total cholesterol, mmol/L (mean ± SD)6.34 ± 1.186.50 ± 1.276.14 ± 1.02**0.03**LDL-C, mmol/L (mean ± SD)4.26 ± 0.944.46 ± 1.004.02 ± 0.81**\< 0.001**HDL-C, mmol/L (mean ± SD)1.29 ± 0.491.30 ± 0.431.28 ± 0.570.79Triglycerides, mmol/L (mean ± SD)2.29 ± 2.002.26 ± 2.212.32 ± 1.720.86Imputed baseline LDL-C (mean ± SD)7.04 ± 2.907.53 ± 2.936.41 ± 2.75**0.007**Lipid-lowering therapy[∗](#tbl1fnlowast){ref-type="table-fn"} (%)76.9%78.0%75.6%0.69Reported goal-inhibiting statin intolerance (%)64.1%66.10%61.6%0.52Any statin (%)60.0%62.4%57.0%0.44Any statin + ezetimibe 10 mg/d (%)15.9%15.6%16.3%0.90High-intensity statin (%)[†](#tbl1fndagger){ref-type="table-fn"}35.4%36.7%33.7%0.67Moderate-intensity statin (%)[†](#tbl1fndagger){ref-type="table-fn"}19.0%21.1%16.3%0.39Low-intensity statin (%)[†](#tbl1fndagger){ref-type="table-fn"}5.6%4.6%7.0%0.47[^1][^2][^3][^4]

In the total group of patients, there were 109 men and 86 women (76% white) with a mean age of 63 ± 12 years; diabetes (29.7%), hypertension (62.1%), past/current smoking (37.9%), and family history of premature ASCVD (59.5%) were common. The on-treatment LDL-C was 4.26 ± 0.94 mmol/L; 76.9% of patients were taking lipid-lowering therapies with 35.4% receiving high-intensity statin (rosuvastatin 20 or 40 mg; atorvastatin 40 or 80 mg/d). An important proportion (64.1%) of all patients reported goal-inhibiting statin intolerance.

A validated clinical application was used to determine a diagnosis of FH incorporating clinical criteria. We have previously established the 95th percentile for LDL-C in a population of \> 3 million subjects. By using a cut-point of LDL-C \> 5.0 mmol/L as the baseline (untreated) value, 140 of 195 patients (72%) had severe hypercholesterolemia, the threshold for considering a diagnosis of FH in adults. The imputed baseline LDL-C was determined to be 7.04 ± 2.90 mmol/L, above the threshold of 5.0 mmol/L for the 95th percentile in adults aged \> 40 years.[@bib8]

A diagnosis of probable/definite FH was found in 54.7%, 49.5%, and 61.5% of patients according to the Simon Broome Register, Dutch Lipid Clinic Network criteria, and the new Canadian FH definition ([Fig. 1](#fig1){ref-type="fig"}), respectively ([Table 2](#tbl2){ref-type="table"}). Overall, approximately 55% of our patients fitted a definition for FH.Table 2Proportion of probable/definite FH in subgroups of patients included in the registry because of FH versus ASCVD, according to known standardized clinical definitions of FHDutch Lipid Clinic NetworkSimon Broome RegisterCanadian definition for FHREACT cohort (n = 195)49.5%54.7%61.5%Subgroups: FH (n = 109)61.7%79.4%78.5%ASCVD (n = 86)34.1%23.5%40.0%[^5]

We then examined the FH and ASCVD groups separately ([Fig. 2](#fig2){ref-type="fig"}). Fewer patients had hypertension in the FH group than in the ASCVD group (51.4% vs. 75.6%, *P* \< 0.001, [Table 1](#tbl1){ref-type="table"}). Surprisingly, body mass index and smoking were not significantly different between the FH and ASCVD groups (*P* = 0.64 and 0.32, respectively), whereas the presence of type 2 diabetes was likely more common in the ASCVD group (*P* = 0.07). [Figure 3](#fig3){ref-type="fig"} shows individual patient data according to the LDL-C at entry into the study and the imputed baseline LDL-C according to the type and dose of medication. [Figure 3](#fig3){ref-type="fig"} shows the FH subgroup of patients (left panel) and those with a diagnosis of ASCVD (right panel) at entry. The on-treatment and imputed baseline LDL-C for the patients with FH were 4.46 ± 1.00 mmol/L and 7.53 ± 2.93 mmol/L, and 4.02 ± 0.81 mmol/L and 6.41 ± 2.75 mmol/L in those with ASCVD, respectively. Although the diagnosis of FH was a requirement, some patients labeled as "FH" by their treating physician lacked the LDL-C criterion, as determined by the accepted FH definitions.Figure 3Current or on-treatment LDL-C and imputed baseline LDL-C based on dose and type of lipid-lowering treatment in the FH (**left**) and ASCVD (**right**) inclusion group separately. The mean ± standard deviation is shown in red. ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol.

Discussion {#sec3}
==========

FH has a prevalence of approximately 0.004 (1/250) and accounts for approximately 0.008 (1/125) patients presenting in an acute coronary care setting.[@bib4], [@bib5], [@bib6] Untreated, FH leads to an inaugural ASCVD presentation in the fourth decade of life in men and 10 years later in women.[@bib3], [@bib12] Registry data from The Netherlands show that early detection of FH through cascade screening and prompt initiation of statin use have led to an improvement in disease-free survival, approaching that of a normal population.[@bib13] Unfortunately, a lack of awareness on the part of physicians, the relative complexity of diagnosis on clinical grounds, and the lack of availability of genetic screening delay the diagnosis of FH until an ASCVD event occurs in many subjects.

In the current study, we focused on subjects with ASCVD and high residual cardiovascular risk because of an elevated LDL-C (\>3.0 mmol/L despite maximally tolerated lipid-lowering therapies). It should be noted that goal-inhibiting statin intolerance was reported in 64% of this highly selected group of patients and that 51% of patients with ASCVD were not taking statins. This analysis of 195 patients from community and specialized clinics reveals that in patients with ASCVD and on-treatment LDL-C \> 3 mmol/L, the prevalence of probable or definite FH is high, which is unrecognized. By using the imputed LDL-C as initial criterion for a diagnosis of FH, many patients have a baseline LDL-C \> 5.0 mmol/L, the threshold for FH in adults aged \> 40 years.[@bib6] In some patients, the imputed LDL-C was \> 13 mmol/L, a threshold considered to reflect severe hypercholesterolemia, possibly homozygous FH. However, our imputed LDL-C estimation has the inherent limitation of presenting an average response to a specific dose of statin and ezetimibe and relies on the assumption that the patient is fully compliant. Therefore, a patient with an on-treatment LDL-C of 7 mmol/L but not taking the prescribed high-dose statin will have an imputed LDL-C \> 13 mmol/L. Excluding all patients with an imputed LDL-C \> 13 mmol/L did not significantly change our conclusions. The mean imputed baseline LDL-C after removal of patients with an imputed LDL-C \> 13 mmol/L was 7.04 ± 2.31 mmol/L for the patients included with a diagnosis of FH and 6.14 ± 2.39 mmol/L for the patients with ASCVD as inclusion criterion (*P* = 0.01).

A diagnosis of FH guides the intensity of therapy, affects prognosis,[@bib5], [@bib14] and has important implications for cascade screening and prevention in first-degree relatives.[@bib15], [@bib16] Early diagnosis and treatment of FH can decrease the risk of ASCVD development. PCSK9 inhibitors have been found to markedly decrease LDL-C in patients with FH with or without a background of statin therapy.[@bib17] In high-risk patients with ASCVD with an elevated residual risk because of elevated LDL-C despite maximally tolerated statin therapy ± ezetimibe, evolocumab and alirocumab reduce cardiovascular outcomes in large, randomized clinical trials.[@bib18], [@bib19] PCSK9 inhibitors are now recommended in such patients by national guidelines in Canada and the United States.[@bib20], [@bib21], [@bib22]

In the present study, we used a practical clinical application to determine the presence of FH in a highly selected population of patients with a prior diagnosis of FH (according to the treating physician) or ASCVD with an elevated residual LDL-C despite maximally tolerated therapy. In the ASCVD high-risk population, 75.6% of patients were on a lipid-lowering therapy and only 33.7% were on high-intensity statins. In fact, approximately 2 of 3 of subjects in both groups reported partial or complete goal-inhibiting statin intolerance, which did not allow the patient to reach the recommended LDL-C target according to the Canadian Cardiovascular Society guidelines.[@bib20] In the patients with ASCVD, 34% to 40% of patients had probable/definite FH according to the Dutch Lipid Clinic Network or the new Canadian definition for FH. The Simon Broome Register criteria fared less well because, in many cases, the total cholesterol criterion was lacking.

Study limitations {#sec3.1}
-----------------

There are important limitations to this study. The relatively small number of subjects included in the registry tends to suggest that this is, fortunately, not a frequently encountered problem and that for a majority of patients, current treatment with statins ± ezetimibe is adequate. The present group of subjects might not effectively represent the Canadian population with ASCVD but nevertheless raise awareness that among Canadians at high risk of cardiovascular disease and elevated LDL-C despite lipid-lowering therapy, a diagnosis of FH should be considered in a significant percentage. Second, the use of an imputed LDL-C may overestimate baseline LDL-C in some patients who are not compliant with their medication and lead to an inaccurate diagnosis of FH. Nevertheless, clinicians should be aware that an elevated LDL-C (\> 3.0 mmol/L) in statin-treated subjects should raise the possibility of underlying FH, and more aggressive LDL-C lowering is warranted, as is cascade screening.

Conclusions {#sec4}
===========

This REACT analysis reveals that a substantial proportion of patients with ASCVD whose LDL-C levels remain well above target have probable or definite FH. Use of an imputed LDL-C in statin-treated patients and simplified tools for FH diagnosis significantly help identify FH in patients. Clinicians should consider using the recently described algorithm to assess the possibility of FH in patients with ASCVD with an LDL \> 3.0 mmol/L despite maximally tolerated statins. Appropriate diagnosis of FH in these patients not only guides aggressive therapy but also has important implications for cascade screening and prevention in first-degree relatives.
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[^1]: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density cholesterol lipoprotein; REACT, Relating Evidence to Achieve Cholesterol Targets; SD, standard deviation.

[^2]: Bold values denote statistical significance at the *P* \< 0.05 level.

[^3]: Any lipid-lowering therapy includes statins, ezetimibe, bile acid sequestrants, niacin, fibrates, and omega-3.

[^4]: High-intensity statin includes atorvastatin 40-80 mg and rosuvastatin 20-40 mg; moderate-intensity statin includes atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, and fluvastatin 40 mg; low-intensity statin includes simvastatin 10 mg, pravastatin 5-20 mg, and fluvastatin 20 mg.

[^5]: ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; REACT, Relating Evidence to Achieve Cholesterol Targets.
